273 related articles for article (PubMed ID: 32474122)
21. An miRNA signature associated with tumor mutation burden in endometrial cancer.
Zhou H; Chen L; Qin M; Lei Y; Li T; Li H; Cheng X
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33141168
[TBL] [Abstract][Full Text] [Related]
22. Systematic profiling of diagnostic and prognostic value of autophagy-related genes for sarcoma patients.
Wang Y; Li J; Shao C; Tang X; Du Y; Xu T; Zhao Z; Hu H; Sheng Y; Hu C; Xi Y
BMC Cancer; 2021 Jan; 21(1):58. PubMed ID: 33435917
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive profiling of immune-related genes in soft tissue sarcoma patients.
Hu C; Chen B; Huang Z; Liu C; Ye L; Wang C; Tong Y; Yang J; Zhao C
J Transl Med; 2020 Sep; 18(1):337. PubMed ID: 32873319
[TBL] [Abstract][Full Text] [Related]
24. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
Front Immunol; 2021; 12():688215. PubMed ID: 34305920
[TBL] [Abstract][Full Text] [Related]
25. Mismatch repair gene
Zhou LZ; Xiao HQ; Chen J
Front Immunol; 2024; 15():1302797. PubMed ID: 38390329
[TBL] [Abstract][Full Text] [Related]
26. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
Gargiulo P; Della Pepa C; Berardi S; Califano D; Scala S; Buonaguro L; Ciliberto G; Brauchli P; Pignata S
Cancer Treat Rev; 2016 Jul; 48():61-8. PubMed ID: 27362548
[TBL] [Abstract][Full Text] [Related]
27. Identification of a metabolism-related gene expression prognostic model in endometrial carcinoma patients.
Jiang P; Sun W; Shen N; Huang X; Fu S
BMC Cancer; 2020 Sep; 20(1):864. PubMed ID: 32894095
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive analysis of prognostic tumor microenvironment-related genes in osteosarcoma patients.
Hu C; Liu C; Tian S; Wang Y; Shen R; Rao H; Li J; Yang X; Chen B; Ye L
BMC Cancer; 2020 Aug; 20(1):814. PubMed ID: 32854645
[TBL] [Abstract][Full Text] [Related]
29. The combined signatures of G protein-coupled receptor family and immune landscape provide a prognostic and therapeutic biomarker in endometrial carcinoma.
Chen S; Luo X; Yang B; Zhuang J; Guo J; Zhu Y; Mo J
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14701-14719. PubMed ID: 37584707
[TBL] [Abstract][Full Text] [Related]
30. Expression patterns of immune checkpoints in acute myeloid leukemia.
Chen C; Liang C; Wang S; Chio CL; Zhang Y; Zeng C; Chen S; Wang C; Li Y
J Hematol Oncol; 2020 Apr; 13(1):28. PubMed ID: 32245463
[TBL] [Abstract][Full Text] [Related]
31. Identification of cuproptosis-related subtypes, establishment of a prognostic model and tumor immune landscape in endometrial carcinoma.
Shan J; Geng R; Zhang Y; Wei J; Liu J; Bai J
Comput Biol Med; 2022 Oct; 149():105988. PubMed ID: 36007289
[TBL] [Abstract][Full Text] [Related]
32. The role of an immune signature for prognosis and immunotherapy response in endometrial cancer.
Meng Y; Yang Y; Zhang Y; Yang X; Li X; Hu C
Am J Transl Res; 2021; 13(2):532-548. PubMed ID: 33594308
[TBL] [Abstract][Full Text] [Related]
33. Multi-omics profiling reveals distinct microenvironment characterization of endometrial cancer.
Cai Y; Chang Y; Liu Y
Biomed Pharmacother; 2019 Oct; 118():109244. PubMed ID: 31352239
[TBL] [Abstract][Full Text] [Related]
34. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
35. Identification of prognostic genes in adrenocortical carcinoma microenvironment based on bioinformatic methods.
Li X; Gao Y; Xu Z; Zhang Z; Zheng Y; Qi F
Cancer Med; 2020 Feb; 9(3):1161-1172. PubMed ID: 31856409
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.
Singh L; Singh MK; Rizvi MA; Pushker N; Bakhshi S; Sen S; Kashyap S
Br J Ophthalmol; 2021 Jan; 105(1):48-56. PubMed ID: 32277010
[TBL] [Abstract][Full Text] [Related]
37. Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data.
Liu Q; Cheng R; Kong X; Wang Z; Fang Y; Wang J
Front Immunol; 2020; 11():558757. PubMed ID: 33329517
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
Pasanen A; Ahvenainen T; Pellinen T; Vahteristo P; Loukovaara M; Bützow R
Am J Surg Pathol; 2020 Feb; 44(2):174-181. PubMed ID: 31651527
[TBL] [Abstract][Full Text] [Related]
39. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
Zhang X; Shi X; Zhao H; Jia X; Yang Y
Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
[TBL] [Abstract][Full Text] [Related]
40. The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness.
Wang Z; Guo X; Gao L; Deng K; Lian W; Bao X; Feng M; Duan L; Zhu H; Xing B
J Clin Endocrinol Metab; 2020 Sep; 105(9):e3207-23. PubMed ID: 32652004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
